<!DOCTYPE html>
<html lang="en">
    
    <head>
        
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <meta name="viewport" content="width=device-width, initial-scale=1">
        
        <title>Concor - Contraindications / Interaction</title>
        
        <!-- Bootstrap's Core CSS -->
        <link rel="stylesheet" href="../assets/css/bootstrap.min.css">
        
        <!-- Font Awesome Icon Library -->
        <link rel="stylesheet" href="../assets/css/font-awesome.min.css">
        
        <!-- IE Viewport CSS Fix -->
        <link rel="stylesheet" href="../assets/css/ie-viewport-fix.css">
        
        <!-- Custom CSS -->
        <link rel="stylesheet" href="../assets/css/style.css">
        
        <!-- Google Fonts -->
        <link href="https://fonts.googleapis.com/css?family=Open+Sans:300,400,700" rel="stylesheet">
        
        <!-- HTML5 Shiv and Respond.JS - HTML5 and CSS3 Media Queries for Legacy Browsers -->
        <!--[if lt IE 9]>
            <script src="assets/js/html5shiv.min.js"></script>
            <script src="assets/js/html5shiv-printshiv.min.js"></script>
            <script src="assets/js/respond.js"></script>
        <![endif]-->
        
    </head>
    
    <body>
       
            <div class="container">
                <div class="row">
                    
                    <div class="col-md-12">
                            <h2 class="head-title">Contraindications / Interaction</h2>
                        <div class="content">
                            <h3>1. Contraindication:</h3>
                            <ul>
                                <li>- Acute heart failure and episodes of congestive heart failure requiring parenteral inotropic therapy.</li>
                                <li>- Second or third degree AV block (without a pacemaker).</li>
                                <li>- Sick sinus syndrome.</li>
                                <li>- Sinoatrial block.</li>
                                <li>- Cardiogenic shock.</li>
                                <li>- Symptomatic bradycardia with fewer than 60 beats per minute before treatment starts.</li>
                                <li>- Symptomatic hypotension (systolic blood pressure &#60; 100 mmHg).</li>
                                <li>- Severe form of peripheral arterial occlusive disease or Raynaud's syndrome.</li>
                                <li>- Severe bronchial asthma.</li>
                                <li>- Untreated phaeochromocytoma.</li>
                                <li>- Metabolic acidosis.</li>
                                <li>- Hypersensitivity to bisoprolol or to any of the excipients according to the composition.</li>
                            </ul>
                            <h3>2. Interactions</h3>
                            <p>Concomitant use of the following is not recommended:</p>
                            <ul>
                                <li>- Calcium antagonists of the verapamil and, to a lesser extent, diltiazem type: negative effect on contractility and AV conduction. Intravenous administration of verapamil may lead to marked hypotension and AV block.</li><br>
                                <li>- Centrally acting antihypertensives (e.g. reserpine, α-methyldopa, clonidine, moxonidine): The hypotensive effect is intensified by the reduction in heart rate and cardiac output, and by vasodilation. Sudden withdrawal of a centrally acting antihypertensive, particularly before withdrawing β-blocker treatment, may increase the risk of rebound hypertension.</li><br>
                                <li>- Class I anti-arrhythmics (e.g. quinidine, lidocaine, phenytoin) in patients with chronic heart failure: They may increase the effect on AV conduction time and the negative inotropic effect of β-receptor blockers.</li><br>
                            </ul>
                            <p>Caution must be exercised during concomitant use of the following:</p>
                            <ul>
                                <li>- Insulin and oral antidiabetics: intensification of the hypoglycemic effect. The warning signs of hypoglycemia (e.g. tachycardia, palpitations or sweating) may be masked or reduced by β- blockers.</li><br>
                                <li>- Calcium antagonists of the dihydropyridine type (e.g. nifedipine, felodipine, amlodipine): There may be an increased risk of hypotension and ventricular pump function may be deteriorated in patients with heart failure.</li><br>
                                <li>- Class III anti-arrhythmics (e.g. amiodarone): possible intensification of the effect on AV conduction time.</li><br>
                                <li>- Cholinergic agonists: AV conduction time may be prolonged and there may be an increased risk of bradycardia.</li><br>
                                <li>- Anaesthetics: attenuation of reflex tachycardia and an increased risk of hypotension.</li><br>
                                <li>- Digitalis glycosides: an increase in AV conduction time, which slows down the heart rate.</li><br>
                                <li>- Non-steroidal anti-inflammatory drugs (NSAIDs): The hypotensive effect may be reduced.</li><br>
                                <li>- β-agonists (e.g. dobutamine): The effect of both substances may be reduced.
                                <li>- Agonists that activate α- and β-receptors (e.g. adrenaline, noradrenaline): a possible increase in blood pressure and exacerbation of intermittent claudication. Such interaction is particularly likely to occur with non-selective β-blockers.</li><br>
                                <li>- Other antihypertensives or medicinal products with hypotensive properties (e.g. tricyclic antidepressants, barbiturates and phenothiazines), including eye drops used to treat glaucoma and alcohol: There is an increased risk of hypotension.</li><br>
                                <li>- Class I anti-arrhythmics (e.g. quinidine, lidocaine, phenytoin) in patients with essential hypertension or angina: They may increase the effect on AV conduction time and the negative inotropic effect of β-receptor blockers.</li>
                            </ul>
                            <p><em>- If any of the following are used concomitantly, please note:</em></p>
                            <ul>
                                <li>- Mefloquine: increased risk of bradycardia.</li>
                                <li>- Monoamine oxidase inhibitors (excluding MAO-B inhibitors): increase in the hypotensive effect of the β-blocker, but also a risk of hypertensive crisis.</li>
                                <li>- Ergotamine derivatives: exacerbation of peripheral circulatory disorders.</li>
                            </ul>
                        </div>
                    </div><!--- End Of Container --->
                </div><!-- End Of Row -->
            </div><!-- End Of Container -->
        
    
        <!-- Scripts -->
        
        <!-- jQuery -->
        <script src="../assets/js/jquery.min.js"></script>
        
        <!-- Bootstrap's JS -->
        <script src="../assets/js/bootstrap.min.js"></script>
        
        <!-- IE Viewport JS Fix -->
        <script src="../assets/js/ie-viewport-fix.js"></script>
        
        <!-- Custom Script -->
        <script src="../assets/js/script.js"></script>
    </body>
</html>